212 related articles for article (PubMed ID: 29305962)
21. Cancer-Associated Fibroblasts Autophagy Enhances Progression of Triple-Negative Breast Cancer Cells.
Wang M; Zhang J; Huang Y; Ji S; Shao G; Feng S; Chen D; Zhao K; Wang Z; Wu A
Med Sci Monit; 2017 Aug; 23():3904-3912. PubMed ID: 28802099
[TBL] [Abstract][Full Text] [Related]
22. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract][Full Text] [Related]
23. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract][Full Text] [Related]
24. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
[TBL] [Abstract][Full Text] [Related]
25. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.
Kashyap A; Umar SM; Dev J R A; Prasad CP
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2177-2184. PubMed ID: 34319041
[TBL] [Abstract][Full Text] [Related]
26. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
27. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
28. VSP-17, a New PPARγ Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin.
Wang Y; Zhu M; Yuan B; Zhang K; Zhong M; Yi W; Xu X; Duan X
Molecules; 2018 Jan; 23(1):. PubMed ID: 29316690
[TBL] [Abstract][Full Text] [Related]
29. IL-6 Impairs the Activity of Vitamin D3 in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer.
Abdel-Mohsen MA; Abo Deif SM; Abou-Shamaa LA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2267-2273. PubMed ID: 31450894
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
Shah P; Gau Y; Sabnis G
Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
[TBL] [Abstract][Full Text] [Related]
31. UNC0638, a G9a inhibitor, suppresses epithelial‑mesenchymal transition‑mediated cellular migration and invasion in triple negative breast cancer.
Liu XR; Zhou LH; Hu JX; Liu LM; Wan HP; Zhang XQ
Mol Med Rep; 2018 Feb; 17(2):2239-2244. PubMed ID: 29207160
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.
Zhang Y; Tian J; Qu C; Peng Y; Lei J; Li K; Zong B; Sun L; Liu S
Breast Cancer; 2021 Jul; 28(4):859-873. PubMed ID: 33569740
[TBL] [Abstract][Full Text] [Related]
33. Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients.
Xu J; Zhang W; Tang L; Chen W; Guan X
Gene; 2018 Sep; 670():7-14. PubMed ID: 29802992
[TBL] [Abstract][Full Text] [Related]
34. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ) inhibits cancer cell metastasis behavior of TNBC via suppressing EMT and VEGF.
Zheng D; Wu Z; Han J; Guan Q; Li Z; Zuo D; Zhang W; Wu Y
Chem Biol Interact; 2020 Sep; 329():109202. PubMed ID: 32717189
[TBL] [Abstract][Full Text] [Related]
35. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
36. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin.
Zhang Z; Sun C; Zhang L; Chi X; Ji J; Gao X; Wang Y; Zhao Z; Liu L; Cao X; Yang Y; Mao W
Biomed Pharmacother; 2019 Jan; 109():1541-1546. PubMed ID: 30551406
[TBL] [Abstract][Full Text] [Related]
37. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
38. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
39. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
[TBL] [Abstract][Full Text] [Related]
40. DNMT1: A key drug target in triple-negative breast cancer.
Wong KK
Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
